Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $273,980.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Monday, January 13th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00.

Kiniksa Pharmaceuticals Price Performance

KNSA traded down $0.42 during trading on Wednesday, hitting $19.28. The stock had a trading volume of 243,957 shares, compared to its average volume of 589,623. The company has a 50 day moving average price of $19.92 and a 200-day moving average price of $22.99. Kiniksa Pharmaceuticals, Ltd. has a one year low of $16.56 and a one year high of $28.15. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -137.70 and a beta of 0.32.

Wall Street Analyst Weigh In

KNSA has been the topic of several recent analyst reports. Evercore ISI boosted their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Wedbush reissued an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $36.60.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently made changes to their positions in KNSA. CWM LLC lifted its position in shares of Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares during the period. nVerses Capital LLC bought a new stake in Kiniksa Pharmaceuticals during the third quarter worth about $80,000. Hennion & Walsh Asset Management Inc. grew its stake in Kiniksa Pharmaceuticals by 7.6% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 195,852 shares of the company’s stock worth $4,894,000 after buying an additional 13,886 shares in the last quarter. Semanteon Capital Management LP acquired a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $551,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock worth $195,000 after acquiring an additional 3,076 shares during the period. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.